Cargando…

Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium

BACKGROUND: Successful treatment of major depressive disorder (MDD) can be challenging, and failures ("treatment-resistant depression" [TRD]) are frequent. Steps to address TRD include increasing antidepressant dose, combining antidepressants, adding adjunctive agents, or using nonpharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vázquez, Gustavo H., Bahji, Anees, Undurraga, Juan, Tondo, Leonardo, Baldessarini, Ross J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358538/ https://www.ncbi.nlm.nih.gov/pubmed/34238049 http://dx.doi.org/10.1177/02698811211013579

Ejemplares similares

Are renal tumors associated with lithium treatment?
por: Baldessarini, Ross J, et al.
Publicado: (2014)

Is (S)-norketamine an alternative antidepressant for esketamine?
por: Hashimoto, Kenji, et al.
Publicado: (2018)

Depression and Mania in Bipolar Disorder
por: Tondo, Leonardo, et al.
Publicado: (2017)

Bipolar depression: a major unsolved challenge
por: Baldessarini, Ross J., et al.
Publicado: (2020)

Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial
por: Xiao, Chunfeng, et al.
Publicado: (2023)

Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)
por: McAdam, Matthew KT, et al.
Publicado: (2023)

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode
por: Basto, M. D. R. D. R. F. D. A., et al.
Publicado: (2023)

First-generation vs second-generation antipsychotic drugs: The ongoing saga
por: Gupta, Sumeet
Publicado: (2010)

Discontinuing psychotropic drug treatment
por: Tondo, Leonardo, et al.
Publicado: (2020)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Methodological considerations regarding Joyce et al. 2016
por: Baethge, Christopher, et al.
Publicado: (2017)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022)

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
por: Solmi, Marco, et al.
Publicado: (2017)

Relationships of affective temperament ratings to diagnosis and morbidity measures in major affective disorders
por: Miola, Alessandro, et al.
Publicado: (2021)

Factors associated with onset‐age in major affective disorders
por: Miola, Alessandro, et al.
Publicado: (2022)

Ketamine for Bipolar Depression: A Systematic Review
por: Bahji, Anees, et al.
Publicado: (2021)

Association of Lithium and Second-Generation Antipsychotics with Neurocognition in Youth with Bipolar Disorder
por: Jiang, Xinyue, et al.
Publicado: (2022)

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
por: Jamieson, Carol, et al.
Publicado: (2023)

F121. DOES RELAPSE CONTRIBUTE TO TREATMENT RESISTANCE? ANTIPSYCHOTIC RESPONSE IN FIRST- VS. SECOND-EPISODE SCHIZOPHRENIA
por: Takeuchi, Hiroyoshi, et al.
Publicado: (2018)

Clinical efficacy and tolerability of Esketamine: a case series
por: Passani, C., et al.
Publicado: (2022)

Clinical use of lithium salts: guide for users and prescribers
por: Tondo, Leonardo, et al.
Publicado: (2019)

Antidepressant and antipsychotic use in an Italian pediatric population
por: Clavenna, Antonio, et al.
Publicado: (2011)

The Potential for Kratom as an Antidepressant and Antipsychotic
por: Johnson, Lindsay E., et al.
Publicado: (2020)

Antidepressants- and antipsychotics-induced hepatotoxicity
por: Todorović Vukotić, Nevena, et al.
Publicado: (2021)

Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
por: Liu, Peng, et al.
Publicado: (2022)

Differences between bipolar disorder types 1 and 2 support the DSM two-syndrome concept
por: Tondo, Leonardo, et al.
Publicado: (2022)

Two bipolar disorders or one? In reply to commentary by Malhi and Bell
por: Tondo, Leonardo, et al.
Publicado: (2022)

Characteristics of rapid cycling in 1261 bipolar disorder patients
por: Miola, Alessandro, et al.
Publicado: (2023)

Pharmacogenomics and clinical response to antipsychotic treatment. Expectations vs reality.
por: Papadimitriou, N., et al.
Publicado: (2023)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

The use of esketamine in the treatment of patients with oral antidepressant-resistant depression: systematic review and meta-analysis
por: Floriano, Idevaldo, et al.
Publicado: (2023)

Guilty until proven innocent
por: Bahji, Anees
Publicado: (2023)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Treg: tolerance vs immunity
por: Biswas, Moanaro, et al.
Publicado: (2015)

An overview of QTc Prolongation with antipsychotics and antidepressants
por: Bhandari, Samrat Singh, et al.
Publicado: (2022)

Predictors of successful discontinuation of antipsychotics and antidepressants
por: Lincoln, Tania M., et al.
Publicado: (2023)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder
por: Wen, X.J., et al.
Publicado: (2014)

Medication Adherence and Persistence in Patients with Severe Major Depressive Disorder with Psychotic Features: Antidepressant and Second-Generation Antipsychotic Therapy Versus Antidepressant Monotherapy
por: Kim-Romo, Dawn N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_amepmjvipsofs8mrstbjsf9l03